Epstein Secrets

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

ence to defend his role in handling the Jeffrey Epstein sexual abuse case. Acosta was a U.S. Attorney who approved the Epstein plea deal in 2008. By CSPAN In the meantime, Epstein will be given a chance to argue that the non-prosecution agreement, executed in 2008, gave him, his schedulers, his allege

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

ence to defend his role in handling the Jeffrey Epstein sexual abuse case. Acosta was a U.S. Attorney who approved the Epstein plea deal in 2008. By CSPAN In the meantime, Epstein will be given a chance to argue that the non-prosecution agreement, executed in 2008, gave him, his schedulers, his allege

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. EFTA00085695 The office also said Collins may have broken House ethics rules by persuad

ence to defend his role in handling the Jeffrey Epstein sexual abuse case. Acosta was a U.S. Attorney who approved the Epstein plea deal in 2008. By CSPAN In the meantime, Epstein will be given a chance to argue that the non-prosecution agreement, executed in 2008, gave him, his schedulers, his allege